Abstract
Hypertension and insulin resistance are associated with reduced coronary vasodilatory capacity, possibly caused by structural changes in the coronary resistance vessels. The goal of this study was to compare the effect of an angiotensin receptor blocker (ARB) with that of a calcium channel blocker (CCB) on coronary flow reserve and insulin resistance among essential hypertensive patients without left ventricular hypertrophy. A total of 40 consecutive essential hypertensive patients were randomized to daily 40 mg telmisartan or 20 mg nifedipine coat-core treatment. Coronary flow velocity reserve (CFVR) measurement using transthoracic Doppler echocardiography and blood tests were performed before and after 12 weeks of treatment. At baseline, blood pressure, CFVR, and homeostasis model assessment of insulin resistance (HOMA-IR) were not significantly different between the two groups. At the end of the treatment period, the telmisartan and nifedipine groups exhibited similar declines in blood pressure. CFVR was improved in the telmisartan group (2.4±0.4 to 2.9±0.4; p<0.01), but there was no difference in the nifedipine group (2.5±0.3 to 2.5±0.3; n.s.). HOMA-IR was improved in the telmisartan group (3.1±1.1 to 1.6±0.7; p<0.01), but there was no difference in the nifedipine group (2.8±1.1 to 2.4±0.7; n.s.). In conclusion, this study demonstrates that antihypertensive therapy with telmisartan, but not nifedipine, has a beneficial effect on coronary microcirculation and insulin resistance among essential hypertensive patients.
Similar content being viewed by others
Article PDF
References
Hozumi T, Yoshida K, Akasaka T, et al: Noninvasive assessment of significant left anterior descending coronary artery stenosis by coronary flow velocity reserve with transthoracic color Doppler echocardiography. Circulation 1998; 97: 1557–1562.
Pichard AD, Frolin R, Smith H, Ambrose J, Meller J : Coronary flow studies in patients with left ventricular hypertrophy of the hypertensive type: evidence for an impaired coronary vascular reserve. Am J Cardiol 1981; 47: 547–554.
Palombo C, Kozakova M, Magagna A, et al: Early impairment of coronary flow reserve and increase in minimum coronary resistance in borderline hypertensive patients. J Hypertens 2000; 18: 453–459.
Nitenberg A, Valensi P, Sachs R, Dalim M, Aptecar E, Attali JR : Impairment of coronary vascular reserve and Ach-induced coronary vasodilation in diabetic patients with angiographically normal coronary arteries and normal ventricular systolic function. Diabetes 1993; 32: 1017–1023.
Nahser PJ Jr, Brown RE, Oskarsson H, Winnifold MD, Rossen JD : Maximal coronary flow reserve and metabolic coronary vasodilatation in patients with diabetes mellitus. Circulation 1995; 91: 635–640.
Morisita R, Higaki J, Miyazaki M, Ogihara T : Possible role of the vascular renin-angiotensin system in hypertension and vascular hypertrophy. Hypertension 1992; 19 ( Suppl 2): S62–S67.
Frohlich ED, Asstein C, Chobanian AV, et al: The heart in hypertension. N Engl J Med 1992; 327: 998–1008.
Froulich ED : Risk mechanisms in hypertensive heart disease. Hypertension 1999; 34: 782–789.
Kitakaze M, Asanuma H, Funaya H, et al: Angiotensin-converting enzyme inhibitor and angiotensin II receptor blockers synergistically increase coronary blood flow in canine ischemic myocardium. J Am Coll Cardiol 2002; 40: 162–166.
Motz W, Strauer BE : Improvement of coronary reserve after long-term therapy with enalapril. Hypertension 1996; 27: 1031–1038.
Schwartzkopff B, Brehm M, Mundhenke M, Stauer BE : Repair of coronary arteries after treatment with perindopril in hypertensive heart disease. Hypertension 2000; 36: 220–225.
Akinboboye OO, Chou RI, Steven RB : Augmentation of myocardial blood flow in hypertensive heart disease by angiotensin antagonists. A comparison of lisinoppril and losartan. J Am Coll Cardiol 2002; 40: 703–709.
Buus NH, Bottcher M, Hermansen F, Sander M, Nielsen TT, Mulvan MJ : Influence of nitric oxide synthase and adrenegic inhibition of adenosine-induced myocardial hyperemia. Circulation 2001; 104: 2305–2310.
Smits P, Williams SB, Hermanson F, Banitt P, Rongen GA, Creager MA : Endothelial release of nitric oxide contributes to the vasodilator effect of adenosine in humans. Circulation 1995; 92: 2135–2141.
Klingbeil AU, John S, Schneider MP, Jacobi J, Handrock R, Schmieder RE : Effect of AT1 receptor blockade on endothelial function in essential hypertension. Am J Hypertens 2003; 16: 123–128.
Prasad A, Tupas-Habis T, Schenke WH, et al: Acute and chronic angiotensin-1 receptor antagonism reserves endothelial dysfunction in atherosclerosis. Circulation 2000; 101: 2349–2354.
Kanemitsu Y, Tsuchiya K, Ohnishi H, et al: Effect of Angiotensin II type 1 receptor blockade on the systemic blood nitric oxide dynamic in N-nitro-L-arginine methyl ester–treated rats. Hypertens Res 2006; 29: 369–374.
Morimoto S, Yano Y, Maki K, Sawada K : Renal and vascular protective effect of telmisartan in patients with essential hypertension. Hypertens Res 2006; 29: 567–572.
Nakamura T, Fujii S, Hoshino J, et al: Selective angiotensin receptor antagonism with valsaltan decrease arterial stiffness independently of blood pressure lowering in hypertensive patients. Hypertens Res 2005; 28: 937–943.
Takami T, Shigemori M : Efficacy of various antihypertensive agents as evaluated by indices of vascular stiffness in elderly hypertensive patients. Hypertens Res 2003; 26: 609–614.
Uchida H, Nakamura Y, Kaihara M, et al: Practical efficacy of termisartan for decreasing morning home blood pressure and pulse wave velocity in patients with mild-to-moderate hypertension. Hypertens Res 2004; 27: 545–550.
Batenburg WW, Garrelds IM, Bernasconi CC, et al: Angiotensin II type 2 receptor–mediated vasodilation in human coronary microarteries. Circulation 2004; 109: 2296–2301.
Prior JO, Quinoneus MJ, Hernandez-Pampaloni M, et al: Coronary circulatory dysfunction in insulin resistance, impaired glucose tolerance, and type 2 diabetes mellitus. Circulation 2005; 111: 2291–2298.
Yokoyama I, Ohtake T, Momomura SI, et al: Hyperglycemia rather than insulin resistance is related to reduced coronary flow reserve in NIDDM. Diabetes 1998; 7: 119–124.
Julius S, Kjeldsen SE, Weber M, et al: Outcome in hypertensive patients at high cardiovascular risk treated with regiments based on valsartan or amrodipine: the VALUE randomized trial. Lancet 2004; 363: 2022–2031.
Yamaguchi K, Ura N, Murakami N, et al: Olmesartan ameliorates insulin sensitivity by modulating tumor necrosis factor-α and cyclic AMP in skeletal muscle. Hypertens Res 2005; 28: 773–778.
Benson SC, Pershadsingh HA, Ho CI, et al: Identification of telmisartan as a unique angiotensin II receptor antagonist with selective PPAR-γ modulating activity. Hypertension 2004; 43: 1–10.
Miura Y, Yamamoto N, Tsunekawa S, et al: Replacement of valsartan and candesartan by telmisartan in hypertensive patients with type 2 diabetes. Diabetes Care 2005; 28: 757–758.
Navalkar S, Parthasarathy S, Santanam N, Khan BV : Irbesartan, an angiotensin type 1 receptor inhibitor, regulate markers of inflammation in patients in with premature atherosclerosis. J Am Coll Cardiol 2001; 37: 440–444.
Dohi Y, Ohashi M, Sugiyama M, Takase H, Sato K, Ueda R : Candesartan reduces oxide stress and inflammation in patients with essential hypertension. Hypertens Res 2003; 26: 691–697.
Kadowaki D, Anraku M, Tasaki Y, et al: Effect of olmesartan on oxidative stress in hemodialysis patients. Hypertens Res 2007; 30: 395–402.
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
About this article
Cite this article
Hinoi, T., Tomohiro, Y., Kajiwara, S. et al. Telmisartan, an Angiotensin II Type 1 Receptor Blocker, Improves Coronary Microcirculation and Insulin Resistance among Essential Hypertensive Patients without Left Ventricular Hypertrophy. Hypertens Res 31, 615–622 (2008). https://doi.org/10.1291/hypres.31.615
Received:
Accepted:
Issue Date:
DOI: https://doi.org/10.1291/hypres.31.615
Keywords
This article is cited by
-
Angiotensin II blockers improve cardiac coronary flow under hemodynamic pressure overload
Hypertension Research (2021)
-
Ageing and microvasculature
Vascular Cell (2014)
-
Coronary Flow Reserve from Mouse to Man—from Mechanistic Understanding to Future Interventions
Journal of Cardiovascular Translational Research (2013)
-
Non-invasive quantification of coronary vascular dysfunction for diagnosis and management of coronary artery disease
Journal of Nuclear Cardiology (2012)
-
Hypertension impairs myocardial blood perfusion reserve in subjects without regional myocardial ischemia
Hypertension Research (2010)